首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Drug Efflux by a Small Multidrug Resistance Protein Is Inhibited by a Transmembrane Peptide
【2h】

Drug Efflux by a Small Multidrug Resistance Protein Is Inhibited by a Transmembrane Peptide

机译:跨膜肽抑制一种小的多药耐药蛋白的药物外流

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Drug-resistant bacteria use several families of membrane-embedded transporters to remove antibiotics from the cell. One such family is the small multidrug resistance proteins (SMRs) that, because of their relatively small size (ca. 110 residues with four transmembrane [TM] helices), must form (at least) dimers to efflux drugs. Here, we use a Lys-tagged synthetic peptide with exactly the same sequence as TM4 of the full-length SMR Hsmr from Halobacterium salinarum [TM4 sequence: AcA(Sar)3-VAGVVGLALIVAGVVVLNVAS-KKK (Sar = N-methylglycine)] to compete with and disrupt the native TM4-TM4 interactions believed to constitute the locus of Hsmr dimerization. Using a cellular efflux assay of the fluorescent SMR substrate ethidium bromide, we determined that bacterial cells containing Hsmr are able to remove cellular ethidium via first-order exponential decay with a rate constant (k) of 10.1 × 10−3 ± 0.7 × 10−3 s−1. Upon treatment of the cells with the TM4 peptide, we observed a saturable ∼60% decrease in the efflux rate constant to 3.7 × 10−3 ± 0.2 × 10−3 s−1. In corresponding experiments with control peptides, including scrambled sequences and a sequence with d-chirality, a decrease in ethidium efflux either was not observed or was marginal, likely from nonspecific effects. The designed peptides did not evoke bacterial lysis, indicating that they act via the α-helicity and membrane insertion propensities of the native TM4 helix. Our overall results suggest that this approach could conceivably be used to design hydrophobic peptides for disruption of key TM-TM interactions of membrane proteins and represent a valuable route to the discovery of new therapeutics.
机译:耐药细菌使用多个膜嵌入转运蛋白家族从细胞中去除抗生素。一个这样的家族是小的多药抗性蛋白(SMR),由于其相对较小的大小(约110个残基,带有四个跨膜TM螺旋),必须形成(至少)二聚体才能外排药物。在这里,我们使用带有Lys标签的合成肽,该肽具有与来自盐杆菌的全长SMR Hsmr的TM4完全相同的序列[TM4序列:AcA(Sar)3-VAGVVGLALIVAGVVVLNVAS-KKK(Sar = N-甲基甘氨酸)]竞争与天然的TM4-TM4相互作用并破坏了它们,这些相互作用被认为构成了Hsmr二聚化的场所。通过荧光SMR底物溴化乙锭的细胞外排测定,我们确定了含有Hsmr的细菌细胞能够通过一阶指数衰减以10.1×10 −3的速率常数(k)去除细胞乙锭。 sup>±0.7×10 −3 s -1 。用TM4肽处理细胞后,我们观察到流出速率常数可降低约60%,降至3.7×10 -3 ±0.2×10 -3 s -1 。在对照肽的相应实验中,包括杂乱的序列和具有d-手性的序列,未观察到乙外排量减少或边缘化减少,可能是由于非特异性作用所致。设计的肽没有引起细菌裂解,表明它们通过天然TM4螺旋的α-螺旋和膜插入倾向起作用。我们的总体结果表明,该方法可以设想用于设计疏水性肽,以破坏膜蛋白的关键TM-TM相互作用,并代表发现新疗法的宝贵途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号